Search Results - Chiriboga, C.A

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Efficacy and safety of nusinersen in infants with spinal muscular atrophy (SMA): Final results from the phase 3 ENDEAR study

    Efficacy and safety of nusinersen in infants with spinal muscular atrophy (SMA): Final results from the phase 3 ENDEAR study by Finkel, R, Kuntz, N, Mercuri, E, Chiriboga, C.A, Darras, B, Topaloglu, H, Montes, J, Su, J, Zhong, Z.J, Gheuens, S, Bennett, C.F, Schneider, E, Farwell, W

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Interim analysis of the phase 3 CHERISH study evaluating nusinersen in patients with later-onset spinal muscular atrophy (SMA): Primary and descriptive secondary endpoints

    Interim analysis of the phase 3 CHERISH study evaluating nusinersen in patients with later-onset spinal muscular atrophy (SMA): Primary and descriptive secondary endpoints by Mercuri, E, Finkel, R, Kirschner, J, Chiriboga, C.A, Kuntz, N, Darras, B, Shieh, P.B, Saito, K, De Vivo, D.C, Mazzone, E.S, Montes, J, Yang, Q, Zhong, Z.J, Gheuens, S, Bennett, C.F, Schneider, E, Farwell, W

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): Results from the shine study

    Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): Results from the shine study by Kirschner, J., Darras, B.T., Farrar, M.A., Mercuri, E., Chiriboga, C.A., Kuntz, N.L., Shieh, P.B., Tulinius, M., Montes, J., Reyna, S.P., Gambino, G., Foster, R., Bhan, I., Wong, J., Farwell, W.

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): Global pivotal phase 3 study program (STR1VE-US, STR1VE-EU, STR1VE-AP)

    Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): Global pivotal phase 3 study program (STR1VE-US, STR1VE-EU, STR1VE-AP) by Mercuri, E., Baranello, G., Day, J.W., Bruno, C., Corti, S., Chiriboga, C.A., Crawford, T.O., Darras, B.T., Finkel, R.S., Connolly, A.M., Iannaccone, S.T., Kuntz, N.L., Masson, R., Peña, L.D.M., Baldinetti, F., Schultz, M., Shieh, P.B., Smith, E.C., Saito, K., Scoto, M., Spector, S.A., Truncated, A. Authors, Sproule, D.M., Mendell, J.R., Muntoni, F.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update

    Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update by Strauss, K.A., Swoboda, K.J., Farrar, M.A., McMillan, H.J., Parsons, J., Krueger, J.M., Iannaccone, S.T., Chiriboga, C.A., Kwon, J.M., Saito, K., Scoto, M., Baldinetti, F., Schultz, M., Kernbauer, E., Farrow, M., Ogrinc, F.G., Kavanagh, S., Feltner, D.E., McGill, B.E., Spector, S.A., L’Italien, J., Sproule, D.M., Muntoni, F.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: